TACC3 promotes epithelial-mesenchymal transition (EMT) through the activation of PI3K/Akt and ERK signaling pathways

Cancer Letters

Volumn 332, Issue 1, 2013, Pages 63-73

  Ha, Geun Hyoung ^a,b   Park, Jong Sup ^c   Breuer, Eun Kyoung Yim ^a,b  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c The Catholic University of Korea   (South Korea)

Author keywords

Akt; EMT; ERKs; PI3K; TACC3

Indexed keywords

BETA ACTIN; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE; NERVE CELL ADHESION MOLECULE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; TRANSFORMING ACIDIC COILED COIL PROTEIN 3; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ARTICLE; CANCER INVASION; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CENTROSOME; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; MITOSIS; MITOSIS SPINDLE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

BETA CATENIN; CELL MOVEMENT; CELL PROLIFERATION; CELL SHAPE; CELL TRANSFORMATION, NEOPLASTIC; ENZYME ACTIVATION; EPITHELIAL-MESENCHYMAL TRANSITION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEK293 CELLS; HELA CELLS; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION;

EID: 84875273076     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.01.013     Document Type: Article

References (108)

1. Turley E.A., Veiseh M., Radisky D.C., Bissell M.J. Mechanisms of disease: epithelial-mesenchymal transition - does cellular plasticity fuel neoplastic progression?. Nat. Clin. Pract. Oncol. 2008, 5:280-290.
2. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 2009, 119:1420-1428.
3. Huber M.A., Kraut N., Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 2005, 17:548-558.
4. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
5. Tanos B., Rodriguez-Boulan E. The epithelial polarity program: machineries involved and their hijacking by cancer. Oncogene 2008, 27:6939-6957.
6. Kang Y., Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004, 118:277-279.
7. Batlle E., Sancho E., Franci C., Dominguez D., Monfar M., Baulida J., Garcia De Herreros A. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol. 2000, 2:84-89.
8. Hajra K.M., Chen D.Y., Fearon E.R. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 2002, 62:1613-1618.
9. Yang J., Mani S.A., Donaher J.L., Ramaswamy S., Itzykson R.A., Come C., Savagner P., Gitelman I., Richardson A., Weinberg R.A. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117:927-939.
10. Eger A., Aigner K., Sonderegger S., Dampier B., Oehler S., Schreiber M., Berx G., Cano A., Beug H., Foisner R. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 2005, 24:2375-2385.
11. Tse J.C., Kalluri R. Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J. Cell. Biochem. 2007, 101:816-829.
12. Gavert N., Ben-Ze'ev A. Epithelial-mesenchymal transition and the invasive potential of tumors. Trends Mol. Med. 2008, 14:199-209.
13. Lee J.M., Dedhar S., Kalluri R., Thompson E.W. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J. Cell Biol. 2006, 172:973-981.
14. Gergely F., Karlsson C., Still I., Cowell J., Kilmartin J., Raff J.W. The TACC domain identifies a family of centrosomal proteins that can interact with microtubules. Proc. Natl. Acad. Sci. USA 2000, 97:14352-14357.
15. Lee M.J., Gergely F., Jeffers K., Peak-Chew S.Y., Raff J.W. Msps/XMAP215 interacts with the centrosomal protein D-TACC to regulate microtubule behaviour. Nat. Cell Biol. 2001, 3:643-649.
16. Sadek C.M., Pelto-Huikko M., Tujague M., Steffensen K.R., Wennerholm M., Gustafsson J.A. TACC3 expression is tightly regulated during early differentiation. Gene Exp. Patterns 2003, 3:203-211.
17. Schneider L., Essmann F., Kletke A., Rio P., Hanenberg H., Wetzel W., Schulze-Osthoff K., Nurnberg B., Piekorz R.P. The transforming acidic coiled coil 3 protein is essential for spindle-dependent chromosome alignment and mitotic survival. J. Biol. Chem. 2007, 282:29273-29283.
18. Gergely F., Draviam V.M., Raff J.W. The ch-TOG/XMAP215 protein is essential for spindle pole organization in human somatic cells. Genes Dev. 2003, 17:336-341.
19. Yao R., Natsume Y., Noda T. TACC3 is required for the proper mitosis of sclerotome mesenchymal cells during formation of the axial skeleton. Cancer Sci. 2007, 98:555-562.
20. Albee A.J., Wiese C. Xenopus TACC3/maskin is not required for microtubule stability but is required for anchoring microtubules at the centrosome. Mol. Biol. Cell 2008, 19:3347-3356.
21. Kinoshita K., Noetzel T.L., Pelletier L., Mechtler K., Drechsel D.N., Schwager A., Lee M., Raff J.W., Hyman A.A. Aurora A phosphorylation of TACC3/maskin is required for centrosome-dependent microtubule assembly in mitosis. J. Cell Biol. 2005, 170:1047-1055.
22. Gomez-Baldo L., Schmidt S., Maxwell C.A., Bonifaci N., Gabaldon T., Vidalain P.O., Senapedis W., Kletke A., Rosing M., Barnekow A., Rottapel R., Capella G., Vidal M., Astrinidis A., Piekorz R.P., Pujana M.A. TACC3-TSC2 maintains nuclear envelope structure and controls cell division. Cell Cycle 2010, 9:1143-1155.
23. LeRoy P.J., Hunter J.J., Hoar K.M., Burke K.E., Shinde V., Ruan J., Bowman D., Galvin K., Ecsedy J.A. Localization of human TACC3 to mitotic spindles is mediated by phosphorylation on Ser558 by Aurora A: a novel pharmacodynamic method for measuring Aurora A activity. Cancer Res. 2007, 67:5362-5370.
24. Bargo S., Raafat A., McCurdy D., Amirjazil I., Shu Y., Traicoff J., Plant J., Vonderhaar B.K., Callahan R. Transforming acidic coiled-coil protein-3 (Tacc3) acts as a negative regulator of Notch signaling through binding to CDC10/Ankyrin repeats. Biochem. Biophys. Res. Commun. 2010, 400:606-612.
25. Angrisano T., Lembo F., Pero R., Natale F., Fusco A., Avvedimento V.E., Bruni C.B., Chiariotti L. TACC3 mediates the association of MBD2 with histone acetyltransferases and relieves transcriptional repression of methylated promoters. Nucl. Acids Res. 2006, 34:364-372.
26. Garriga-Canut M., Orkin S.H. Transforming acidic coiled-coil protein 3 (TACC3) controls friend of GATA-1 (FOG-1) subcellular localization and regulates the association between GATA-1 and FOG-1 during hematopoiesis. J. Biol. Chem. 2004, 279:23597-23605.
27. Duncan C.G., Killela P.J., Payne C.A., Lampson B., Chen W.C., Liu J., Solomon D., Waldman T., Towers A.J., Gregory S.G., McDonald K.L., McLendon R.E., Bigner D.D., Yan H. Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget 2010, 1:265-277.
28. Kiemeney L.A., Sulem P., Besenbacher S., Vermeulen S.H., Sigurdsson A., Thorleifsson G., Gudbjartsson D.F., Stacey S.N., Gudmundsson J., Zanon C., Kostic J., Masson G., Bjarnason H., Palsson S.T., Skarphedinsson O.B., Gudjonsson S.A., Witjes J.A., Grotenhuis A.J., Verhaegh G.W., Bishop D.T., Sak S.C., Choudhury A., Elliott F., Barrett J.H., Hurst C.D., de Verdier P.J., Ryk C., Rudnai P., Gurzau E., Koppova K., Vineis P., Polidoro S., Guarrera S., Sacerdote C., Campagna M., Placidi D., Arici C., Zeegers M.P., Kellen E., Gutierrez B.S., Sanz-Velez J.I., Sanchez-Zalabardo M., Valdivia G., Garcia-Prats M.D., Hengstler J.G., Blaszkewicz M., Dietrich H., Ophoff R.A., van den Berg L.H., Alexiusdottir K., Kristjansson K., Geirsson G., Nikulasson S., Petursdottir V., Kong A., Thorgeirsson T., Mungan N.A., Lindblom A., van Es M.A., Porru S., Buntinx F., Golka K., Mayordomo J.I., Kumar R., Matullo G., Steineck G., Kiltie A.E., Aben K.K., Jonsson E., Thorsteinsdottir U., Knowles M.A., Rafnar T., Stefansson K. A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat. Genet. 2010, 42:415-419.
29. Malgeri U., Baldini L., Perfetti V., Fabris S., Vignarelli M.C., Colombo G., Lotti V., Compasso S., Bogni S., Lombardi L., Maiolo A.T., Neri A. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts. Cancer Res. 2000, 60:4058-4061.
30. Wang M., Chu H., Yan F., Qin C., Li P., Yuan L., Yin C., Xu J., Zhang Z. Chromosome 4p16.3 variant modify bladder cancer risk in a Chinese population. Carcinogenesis 2011, 32:872-875.
31. Gusella J.F., Wexler N.S., Conneally P.M., Naylor S.L., Anderson M.A., Tanzi R.E., Watkins P.C., Ottina K., Wallace M.R., Sakaguchi A.Y., et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 1983, 306:234-238.
32. Finelli P., Fabris S., Zagano S., Baldini L., Intini D., Nobili L., Lombardi L., Maiolo A.T., Neri A. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by double-color fluorescent in situ hybridization. Blood 1999, 94:724-732.
33. Castro P., Creighton C.J., Ozen M., Berel D., Mims M.P., Ittmann M. Genomic profiling of prostate cancers from African American men. Neoplasia 2009, 11:305-312.
34. Shivapurkar N., Sood S., Wistuba II, Virmani A.K., Maitra A., Milchgrub S., Minna J.D., Gazdar A.F. Multiple regions of chromosome 4 demonstrating allelic losses in breast carcinomas. Cancer Res. 1999, 59:3576-3580.
35. Shivapurkar N., Maitra A., Milchgrub S., Gazdar A.F. Deletions of chromosome 4 occur early during the pathogenesis of colorectal carcinoma. Hum. Pathol. 2001, 32:169-177.
36. Still I.H., Vince P., Cowell J.K. The third member of the transforming acidic coiled coil-containing gene family, TACC3, maps in 4p16, close to translocation breakpoints in multiple myeloma, and is upregulated in various cancer cell lines. Genomics 1999, 58:165-170.
37. D. Singh, J.M. Chan, P. Zoppoli, F. Niola, R. Sullivan, A. Castano, E.M. Liu, J. Reichel, P. Porrati, S. Pellegatta, K. Qiu, Z. Gao, M. Ceccarelli, R. Riccardi, D.J. Brat, A. Guha, K. Aldape, J.G. Golfinos, D. Zagzag, T. Mikkelsen, G. Finocchiaro, A. Lasorella, R. Rabadan, A. Iavarone, Transforming fusions of FGFR and TACC genes in human glioblastoma, Science (2012).
38. Lauffart B., Vaughan M.M., Eddy R., Chervinsky D., DiCioccio R.A., Black J.D., Still I.H. Aberrations of TACC1 and TACC3 are associated with ovarian cancer. BMC Womens Health 2005, 5:8.
39. Ma X.J., Salunga R., Tuggle J.T., Gaudet J., Enright E., McQuary P., Payette T., Pistone M., Stecker K., Zhang B.M., Zhou Y.X., Varnholt H., Smith B., Gadd M., Chatfield E., Kessler J., Baer T.M., Erlander M.G., Sgroi D.C. Gene expression profiles of human breast cancer progression. Proc. Natl. Acad. Sci. USA 2003, 100:5974-5979.
40. Jung C.K., Jung J.H., Park G.S., Lee A., Kang C.S., Lee K.Y. Expression of transforming acidic coiled-coil containing protein 3 is a novel independent prognostic marker in non-small cell lung cancer. Pathol. Int. 2006, 56:503-509.
41. Ulisse S., Baldini E., Toller M., Delcros J.G., Gueho A., Curcio F., De Antoni E., Giacomelli L., Ambesi-Impiombato F.S., Bocchini S., D'Armiento M., Arlot-Bonnemains Y. Transforming acidic coiled-coil 3 and Aurora-A interact in human thyrocytes and their expression is deregulated in thyroid cancer tissues. Endocr. Relat. Cancer 2007, 14:827-837.
42. Yim E.K., Tong S.Y., Ho E.M., Bae J.H., Um S.J., Park J.S. Anticancer effects on TACC3 by treatment of paclitaxel in HPV-18 positive cervical carcinoma cells. Oncol. Rep. 2009, 21:549-557.
43. Kim C.K., Lee S.B., Nguyen T.L., Lee K.H., Um S.H., Kim J., Ahn J.Y. Long isoform of ErbB3 binding protein, p48, mediates protein kinase B/Akt-dependent HDM2 stabilization and nuclear localization. Exp. Cell Res. 2012, 318:136-143.
44. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
45. Wu Q., Qin S.K., Teng F.M., Chen C.J., Wang R. Lobaplatin arrests cell cycle progression in human hepatocellular carcinoma cells. J. Hematol. Oncol. 2010, 3:43.
46. Ye Y., Xiao Y., Wang W., Yearsley K., Gao J.X., Shetuni B., Barsky S.H. ERalpha signaling through slug regulates E-cadherin and EMT. Oncogene 2010, 29:1451-1462.
47. Lee H.J., Hwang H.I., Jang Y.J. Mitotic DNA damage response: polo-like kinase-1 is dephosphorylated through ATM-Chk1 pathway. Cell Cycle 2010, 9:2389-2398.
48. Rhodes D.R., Kalyana-Sundaram S., Mahavisno V., Varambally R., Yu J., Briggs B.B., Barrette T.R., Anstet M.J., Kincead-Beal C., Kulkarni P., Varambally S., Ghosh D., Chinnaiyan A.M. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007, 9:166-180.
49. Zhai Y., Kuick R., Nan B., Ota I., Weiss S.J., Trimble C.L., Fearon E.R., Cho K.R. Gene expression analysis of preinvasive and invasive cervical squamous cell carcinomas identifies HOXC10 as a key mediator of invasion. Cancer Res. 2007, 67:10163-10172.
50. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., Richardson A.L., Polyak K., Tubo R., Weinberg R.A. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557-563.
51. Hou J., Aerts J., den Hamer B., van Ijcken W., den Bakker M., Riegman P., van der Leest C., van der Spek P., Foekens J.A., Hoogsteden H.C., Grosveld F., Philipsen S. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One 2010, 5:e10312.
52. Sun L., Hui A.M., Su Q., Vortmeyer A., Kotliarov Y., Pastorino S., Passaniti A., Menon J., Walling J., Bailey R., Rosenblum M., Mikkelsen T., Fine H.A. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 2006, 9:287-300.
53. D'Errico M., de Rinaldis E., Blasi M.F., Viti V., Falchetti M., Calcagnile A., Sera F., Saieva C., Ottini L., Palli D., Palombo F., Giuliani A., Dogliotti E. Genome-wide expression profile of sporadic gastric cancers with microsatellite instability. Eur. J. Cancer 2009, 45:461-469.
54. Roessler S., Jia H.L., Budhu A., Forgues M., Ye Q.H., Lee J.S., Thorgeirsson S.S., Sun Z., Tang Z.Y., Qin L.X., Wang X.W. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 2010, 70:10202-10212.
55. Hong Y., Downey T., Eu K.W., Koh P.K., Cheah P.Y. A 'metastasis-prone' signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics. Clin. Exp. Metastasis 2010, 27:83-90.
56. Bonome T., Levine D.A., Shih J., Randonovich M., Pise-Masison C.A., Bogomolniy F., Ozbun L., Brady J., Barrett J.C., Boyd J., Birrer M.J. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 2008, 68:5478-5486.
57. Sanchez-Carbayo M., Socci N.D., Lozano J., Saint F., Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J. Clin. Oncol. 2006, 24:778-789.
58. Talantov D., Mazumder A., Yu J.X., Briggs T., Jiang Y., Backus J., Atkins D., Wang Y. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin. Cancer Res. 2005, 11:7234-7242.
59. Grutzmann R., Pilarsky C., Ammerpohl O., Luttges J., Bohme A., Sipos B., Foerder M., Alldinger I., Jahnke B., Schackert H.K., Kalthoff H., Kremer B., Kloppel G., Saeger H.D. Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. Neoplasia 2004, 6:611-622.
60. Hu N., Clifford R.J., Yang H.H., Wang C., Goldstein A.M., Ding T., Taylor P.R., Lee M.P. Genome wide analysis of DNA copy number neutral loss of heterozygosity (CNNLOH) and its relation to gene expression in esophageal squamous cell carcinoma. BMC Genom. 2010, 11:576.
61. Kong C., Wang C., Wang L., Ma M., Niu C., Sun X., Du J., Dong Z., Zhu S., Lu J., Huang B. NEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancer. PLoS One 2011, 6:e22666.
62. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J. Clin. Invest. 2009, 119:1417-1419.
63. Yilmaz M., Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009, 28:15-33.
64. Sarrio D., Rodriguez-Pinilla S.M., Hardisson D., Cano A., Moreno-Bueno G., Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008, 68:989-997.
65. Orsulic S., Huber O., Aberle H., Arnold S., Kemler R. E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1-mediated transactivation. J. Cell Sci. 1999, 112(Pt 8):1237-1245.
66. Li J., Zhou B.P. Activation of beta-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer 2011, 11:49.
67. Kim K., Lu Z., Hay E.D. Direct evidence for a role of beta-catenin/LEF-1 signaling pathway in induction of EMT. Cell Biol. Int. 2002, 26:463-476.
68. Schramp M., Thapa N., Heck J., Anderson R. PIPKIgamma regulates beta-catenin transcriptional activity downstream of growth factor receptor signaling. Cancer Res. 2011, 71:1282-1291.
69. Yim E.K., Peng G., Dai H., Hu R., Li K., Lu Y., Mills G.B., Meric-Bernstam F., Hennessy B.T., Craven R.J., Lin S.Y. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 2009, 15:304-314.
70. Lin S.Y., Xia W., Wang J.C., Kwong K.Y., Spohn B., Wen Y., Pestell R.G., Hung M.C. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc. Natl. Acad. Sci. USA 2000, 97:4262-4266.
71. Michaelson J.S., Leder P. Beta-catenin is a downstream effector of Wnt-mediated tumorigenesis in the mammary gland. Oncogene 2001, 20:5093-5099.
72. He T.C., Sparks A.B., Rago C., Hermeking H., Zawel L., da Costa L.T., Morin P.J., Vogelstein B., Kinzler K.W. Identification of c-MYC as a target of the APC pathway. Science 1998, 281:1509-1512.
73. Shtutman M., Zhurinsky J., Simcha I., Albanese C., D'Amico M., Pestell R., Ben-Ze'ev A. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci. USA 1999, 96:5522-5527.
74. Tetsu O., McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999, 398:422-426.
75. Jope R.S., Johnson G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 2004, 29:95-102.
76. Orford K., Crockett C., Jensen J.P., Weissman A.M., Byers S.W. Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. J. Biol. Chem. 1997, 272:24735-24738.
77. Zhou B.P., Deng J., Xia W., Xu J., Li Y.M., Gunduz M., Hung M.C. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat. Cell Biol. 2004, 6:931-940.
78. Doble B.W., Woodgett J.R. Role of glycogen synthase kinase-3 in cell fate and epithelial-mesenchymal transitions. Cells Tissues Organs 2007, 185:73-84.
79. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378:785-789.
80. Cohen P., Frame S. The renaissance of GSK3. Nat. Rev. Mol. Cell Biol. 2001, 2:769-776.
81. Barbera M.J., Puig I., Dominguez D., Julien-Grille S., Guaita-Esteruelas S., Peiro S., Baulida J., Franci C., Dedhar S., Larue L., Garcia de Herreros A. Regulation of Snail transcription during epithelial to mesenchymal transition of tumor cells. Oncogene 2004, 23:7345-7354.
82. Chen H., Zhu G., Li Y., Padia R.N., Dong Z., Pan Z.K., Liu K., Huang S. Extracellular signal-regulated kinase signaling pathway regulates breast cancer cell migration by maintaining slug expression. Cancer Res. 2009, 69:9228-9235.
83. Cai G., Wang J., Xin X., Ke Z., Luo J. Phosphorylation of glycogen synthase kinase-3 beta at serine 9 confers cisplatin resistance in ovarian cancer cells. Int. J. Oncol. 2007, 31:657-662.
84. Buccione R., Caldieri G., Ayala I. Invadopodia: specialized tumor cell structures for the focal degradation of the extracellular matrix. Cancer Metastasis Rev. 2009, 28:137-149.
85. Chetty C., Bhoopathi P., Joseph P., Chittivelu S., Rao J.S., Lakka S. Adenovirus-mediated small interfering RNA against matrix metalloproteinase-2 suppresses tumor growth and lung metastasis in mice. Mol. Cancer Ther. 2006, 5:2289-2299.
86. Nieto M.A. The snail superfamily of zinc-finger transcription factors. Nat. Rev. Mol. Cell Biol. 2002, 3:155-166.
87. Hong K.O., Kim J.H., Hong J.S., Yoon H.J., Lee J.I., Hong S.P., Hong S.D. Inhibition of Akt activity induces the mesenchymal-to-epithelial reverting transition with restoring E-cadherin expression in KB and KOSCC-25B oral squamous cell carcinoma cells. J. Exp. Clin. Cancer Res. 2009, 28:28.
88. Conacci-Sorrell M., Simcha I., Ben-Yedidia T., Blechman J., Savagner P., Ben-Ze'ev A. Autoregulation of E-cadherin expression by cadherin-cadherin interactions: the roles of beta-catenin signaling, Slug, and MAPK. J. Cell Biol. 2003, 163:847-857.
89. Voisin L., Saba-El-Leil M.K., Julien C., Fremin C., Meloche S. Genetic demonstration of a redundant role of extracellular signal-regulated kinase 1 (ERK1) and ERK2 mitogen-activated protein kinases in promoting fibroblast proliferation. Mol. Cell Biol. 2010, 30:2918-2932.
90. Shin S., Blenis J. ERK2/Fra1/ZEB pathway induces epithelial-to-mesenchymal transition. Cell Cycle 2010, 9:2483-2484.
91. Lloyd A.C. Distinct functions for ERKs?. J. Biol. 2006, 5:13.
92. Marchi M., D'Antoni A., Formentini I., Parra R., Brambilla R., Ratto G.M., Costa M. The N-terminal domain of ERK1 accounts for the functional differences with ERK2. PLoS One 2008, 3:e3873.
93. Shin S., Dimitri C.A., Yoon S.O., Dowdle W., Blenis J. ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol. Cell 2010, 38:114-127.
94. von Thun A., Birtwistle M., Kalna G., Grindlay J., Strachan D., Kolch W., von Kriegsheim A., Norman J.C. ERK2 drives tumour cell migration in three-dimensional microenvironments by suppressing expression of Rab17 and liprin-beta2. J. Cell Sci. 2012, 125:1465-1477.
95. Schonrath K., Klein-Szanto A.J., Braunewell K.H. The putative tumor suppressor VILIP-1 counteracts epidermal growth factor-induced epidermal-mesenchymal transition in squamous carcinoma cells. PLoS One 2012, 7:e33116.
96. Wendt M.K., Smith J.A., Schiemann W.P. Transforming growth factor-beta-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Oncogene 2010, 29:6485-6498.
97. Lee M.Y., Chou C.Y., Tang M.J., Shen M.R. Epithelial-mesenchymal transition in cervical cancer: correlation with tumor progression, epidermal growth factor receptor overexpression, and snail up-regulation. Clin. Cancer Res. 2008, 14:4743-4750.
98. Graham T.R., Zhau H.E., Odero-Marah V.A., Osunkoya A.O., Kimbro K.S., Tighiouart M., Liu T., Simons J.W., O'Regan R.M. Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res. 2008, 68:2479-2488.
99. Ahmed N., Maines-Bandiera S., Quinn M.A., Unger W.G., Dedhar S., Auersperg N. Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium. Am. J. Physiol. Cell Physiol. 2006, 290:C1532-1542.
100. Cheng J.C., Klausen C., Leung P.C. Hydrogen peroxide mediates EGF-induced down-regulation of E-cadherin expression via p38 MAPK and snail in human ovarian cancer cells. Mol. Endocrinol. 2010, 24:1569-1580.
101. Cheng J.C., Auersperg N., Leung P.C. EGF-induced EMT and invasiveness in serous borderline ovarian tumor cells: a possible step in the transition to low-grade serous carcinoma cells?. PLoS One 2012, 7:e34071.
102. Cully M., Shiu J., Piekorz R.P., Muller W.J., Done S.J., Mak T.W. Transforming acidic coiled coil 1 promotes transformation and mammary tumorigenesis. Cancer Res. 2005, 65:10363-10370.
103. Schuendeln M.M., Piekorz R.P., Wichmann C., Lee Y., McKinnon P.J., Boyd K., Takahashi Y., Ihle J.N. The centrosomal, putative tumor suppressor protein TACC2 is dispensable for normal development, and deficiency does not lead to cancer. Mol. Cell Biol. 2004, 24:6403-6409.
104. Lauffart B., Gangisetty O., Still I.H. Molecular cloning, genomic structure and interactions of the putative breast tumor suppressor TACC2. Genomics 2003, 81:192-201.
105. Yao J.E., Yan M., Guan Z., Pan C.B., Xia L.P., Li C.X., Wang L.H., Long Z.J., Zhao Y., Li M.W., Zheng F.M., Xu J., Lin D.J., Liu Q. Aurora-A down-regulates IkappaBalpha via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival. Mol. Cancer 2009, 8:95.
106. Tseng Y.S., Lee J.C., Huang C.Y., Liu H.S. Aurora-A overexpression enhances cell-aggregation of Ha-ras transformants through the MEK/ERK signaling pathway. BMC Cancer 2009, 9:435.
107. Wan X.B., Long Z.J., Yan M., Xu J., Xia L.P., Liu L., Zhao Y., Huang X.F., Wang X.R., Zhu X.F., Hong M.H., Liu Q. Inhibition of Aurora-A suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells. Carcinogenesis 2008, 29:1930-1937.
108. Schmidt S., Essmann F., Cirtea I.C., Kuck F., Thakur H.C., Singh M., Kletke A., Janicke R.U., Wiek C., Hanenberg H., Ahmadian M.R., Schulze-Osthoff K., Nurnberg B., Piekorz R.P. The centrosome and mitotic spindle apparatus in cancer and senescence. Cell Cycle 2010, 9:4469-4473.